Companies › Zhejiang ACEA Pharmaceutical
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| STI-6129 anti-CD38 antibody-drug conjugate with duostatin tubulin inhibitor | CD38 | Phase 1 | Relapsed or Refractory Multiple Myeloma | Dec 2026 |
| STI-8591 | – | Phase 1 | AML, Adult | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05947344 | STI-8591 | Phase 1 | AML, Adult | Oncology | Dec 2025 |
| NCT05565807 | STI-6129 | Phase 1 | Relapsed or Refractory Multiple Myeloma | Oncology | Dec 2026 |
Takeda Johnson & Johnson (Janssen) Biogen CASI pharmaceuticals Sanofi Celltrion GSK Sinocelltech
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.